PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

This activity is provided in partnership with the University of Oklahoma Health.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.  

PROGRAM OVERVIEW

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are fibrosing lung diseases associated with substantial morbidity and mortality. Recent updates to the classification of interstitial pneumonias (IPs) and the approval of new targeted therapies highlight the need for clinicians to be educated on the latest information to continue to be able to accurately classify disease, recognize progression earlier, and understand the biologic pathways driving fibrosis. Challenges in distinguishing stable from advancing disease and interpreting changes in symptoms, physiology, and imaging can complicate management decisions, while knowledge of key fibrotic pathways helps inform current and emerging treatment strategies.

Join us for a live-virtual webcast, Defining and Diagnosing IPF and PPF: Understanding the Mechanisms Behind New and Emerging Treatments, where expert faculty will review the updated classification framework for IPs, discuss practical approaches to identifying and monitoring disease progression, and examine the mechanisms, efficacy, and safety of current and emerging therapies. Through case-based discussion, faculty will provide practical insights to support evidence-based, patient-centered management of IPF and PPF.